Successful use of danaparoid in two pregnant women with heart valve prosthesis and heparin-induced thrombocytopenia type ii (hit)

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 4, 2009, Pages 461-464

  Gerhardt, Andrea ^a   Scharf, Rüdiger E ^a   Zotz, Rainer B ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Institute of Haemostasis   (Germany)

Author keywords

Danaparoid; HIT type II; Mechanical heart valve; Pregnancy

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 10A; DANAPAROID; HEPARIN; PHENPROCOUMON;

ADULT; ANTIBODY BLOOD LEVEL; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BACTERIAL ENDOCARDITIS; BLEEDING; CASE REPORT; CESAREAN SECTION; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOPROSTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HEART VALVE PROSTHESIS; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERTENSION; MITRAL VALVE REPLACEMENT; PLACENTA HEMATOMA; PREECLAMPSIA; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; PROTEINURIA; SAINT JUDE HEART VALVE PROSTHESIS; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL; TRICUSPID VALVE PROSTHESIS; TRICUSPID VALVE REPLACEMENT;

ADULT; ANTICOAGULANTS; CHONDROITIN SULFATES; DERMATAN SULFATE; FEMALE; HEART VALVE PROSTHESIS; HEPARIN; HEPARITIN SULFATE; HUMANS; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; THROMBOCYTOPENIA; THROMBOSIS;

EID: 69749104731     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608322173     Document Type: Article

References (17)

1. Chan WS, Anand S., Ginsberg JS Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med. 2000 ; 160: 191-196.
2. Reimold SC, Rutherford JD Valvular heart disease in pregnancy. N Engl J Med. 2003 ; 349: 52-59.
3. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004 ; 126: 311S - 337S.
4. Meuleman DG Orgaran (Org 10172): its pharmacological profile in experimental models. Haemostasis. 1992 ; 22: 58-65.
5. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998 ; 79: 1-7.
6. Chong BH, Gallus AS, Cade JF, et al. Prospective open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis. Thromb Haemost. 2001 ; 86: 1170-1175.
7. Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost. 2006 ; 95: 967-981.
8. Magnani HN Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org10172). Thromb Haemost. 1993 ; 70: 554-561.
9. de Valk HW, Banga JD, Wester JW, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism: a randomized controlled trial. Ann Intern Med. 1995 ; 123: 1-9.
10. Danhof M., de Boer A., Magnani HN, Stiekema JC Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis. 1992 ; 22: 73-84.
11. Magnani HN, Beyering R., Cate JW Orgaran® anticoagulation for cardiopulmonary by-pass in patients with heparin-induced thrombocytopenia. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia, PA: Hanley & Belfus; 1997: 487-500.
12. Roberts N., Ross D., Flint SK, Arya R., Blott M. Thromboembolism in pregnant women with mechanical prosthetic heart valves anticoagulated with low molecular weight heparin. Br J Obstet Gynaecol. 2001 ; 108: 327-329.
13. Leyh RG, Fischer S., Ruhparwar A., Haverich A. Anticoagulation for prosthetic heart valves during pregnancy: is low-molecular-weight heparin an alternative. Eur J Cardiothorac Surg. 2002 ; 21: 577-579. (Pubitemid 34224829)
14. Mahesh B., Evans S., Bryan AJ Failure of low molecular-weight heparin in the prevention of prosthetic mitral valve thrombosis during pregnancy: case report and review of options for anticoagulation. J Heart Valve Dis. 2002 ; 11: 745-750.
15. Lev-Ran O., Kramer A., Gurevitch J., Shapira I., Mohr R. Low molecular-weight heparin for prosthetic heart valves: treatment failure. Ann Thorac Surg. 2000 ; 69: 264-265.
16. Bates SM, Greer IA, Hirsh J., Ginsberg JS Use of antithrombotic agents during pregnancy. Chest. 2004 ; 126: 627S - 644S.
17. Lindhoff-Last E., Kreutzenbeck HJ, Magnani HN Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost. 2005 ; 93: 63-69.